Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NISCI: NG-101 in Acute Cervical Spinal Cord Injury
NCT03935321Phase 2Completed
- Sponsor
- University of Zurich
- Start
- May 2019
- Primary completion
- Feb 2023
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial in acute cervical spinal cord injury (ACSCI) comparing NG-101 Arm with Placebo Arm (2 arms). Primary endpoint: Upper Extremity Motor Score at 24 weeks. Started May 2019; status: completed.
02
Drugs
metopimazine
03
Conditions
acute cervical spinal cord injury (ACSCI)
Beyond the preview
Go deeper on NCT03935321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03935321.